<?xml version='1.0' encoding='ISO-8859-1'?>
<xml>
<title>Illinois General Assembly - Bill Status for SB 3024         </title>
<shortdesc>CONTR SUB-PMP-CONFIDENTIALITY</shortdesc>
<sponsor>
<sponsorhead1>Senate Sponsors</sponsorhead1><sponsors>Sen. Melinda Bush</sponsors>
<sponsorhead2>House Sponsors</sponsorhead2><altsponsors>(Rep. Kathleen Willis-Joyce Mason-Deb Conroy, Nicholas K. Smith, La Shawn K. Ford, Edgar Gonzalez, Jr., Kelly M. Cassidy, Michael J. Zalewski and Camille Y. Lilly)</altsponsors>
</sponsor>
<lastaction>
<statusdate>5/6/2022</statusdate><chamber>Senate</chamber><action>Public Act . . . . . . . . . 102-0751</action>
</lastaction>
<synopsis>
<synopsistitle></synopsistitle>
<reference>720 ILCS 570/318</reference><aliasreference></aliasreference><SynopsisText>Amends the Illinois Controlled Substances Act. Provides that in accordance with an agreement entered into with the Department of Human Services, an authorized employee of a county or municipal health department or the Department of Public Health shall have access to data from the prescription inquiry system for any of the following purposes: (1) developing education programs or public health interventions relating to specific prescribing practices, controlled substances and the prevention of fraud and abuse; or (2) conducting analyses and publish reports on prescribing trends in their respective jurisdictions. Provides that analyses and reports must not include information that identifies, by name, license, or address, any practitioner, dispenser, ultimate user, or other person administering a controlled substance. Provides that any county or municipal health department accessing data from the system shall implement appropriate technical and physical safeguards to ensure the privacy and security of data obtained from the system.</SynopsisText><synopsistitle>Senate Floor Amendment No. 1</synopsistitle>
<SynopsisText>Replaces everything after the enacting clause. Amends the Illinois Controlled Substances Act. Provides that, in accordance with a confidentiality agreement entered into with the Department of Human Services, a medical director, or a public health administrator and their delegated analysts, of a county or municipal health department or the Department of Public Health shall have access to data from the prescription monitoring system for any of the following purposes: (1) developing education programs or public health interventions relating to prescribing trends and controlled substance use; or (2) conducting analyses and publish reports on prescribing trends in their respective jurisdictions. Provides that, at a minimum, the confidentiality agreement entered into with the Department shall: (i) prohibit analysis and reports produced under subparagraph (2) from including information that identifies, by name, license, or address, any practitioner, dispenser, ultimate user, or other person administering a controlled substance; and (ii) specify the appropriate technical and physical safeguards that the county or municipal health department must implement to ensure the privacy and security of data obtained from the system. Provides that the data from the system shall not be admissible as evidence, nor discoverable in any action of any kind in any court or before any tribunal, board, agency, or person. Provides that the disclosure of any such information or data, whether proper or improper, shall not waive or have any effect upon its confidentiality, non-discoverability, or non-admissibility. Provides that, notwithstanding any other provision of the Act, neither the Prescription Monitoring Program nor any other person shall disclose any information in violation of the restrictions and requirements implemented under Public Act 102-527 concerning opioid treatment programs licensed or certified by the Department of Human Services' Division of Substance Use Prevention and Recovery that are authorized by the federal Drug Enforcement Administration to prescribe Schedule II, III, IV, or V controlled substances for the treatment of opioid use disorders.</SynopsisText></synopsis>
<actions>
<statusdate>1/5/2022</statusdate><chamber>Senate</chamber><action>Filed with Secretary by Sen. Melinda Bush</action>
<statusdate>1/5/2022</statusdate><chamber>Senate</chamber><action>First Reading</action>
<statusdate>1/5/2022</statusdate><chamber>Senate</chamber><action>Referred to Assignments</action>
<statusdate>1/11/2022</statusdate><chamber>Senate</chamber><action>Assigned to Health</action>
<statusdate>1/18/2022</statusdate><chamber>Senate</chamber><action>Postponed - Health</action>
<statusdate>2/7/2022</statusdate><chamber>Senate</chamber><action>Do Pass Health;  012-000-000</action>
<statusdate>2/7/2022</statusdate><chamber>Senate</chamber><action>Placed on Calendar Order of 2nd Reading February 8, 2022</action>
<statusdate>2/15/2022</statusdate><chamber>Senate</chamber><action>Senate Floor Amendment No. 1 Filed with Secretary by Sen. Melinda Bush</action>
<statusdate>2/15/2022</statusdate><chamber>Senate</chamber><action>Senate Floor Amendment No. 1 Referred to Assignments</action>
<statusdate>2/22/2022</statusdate><chamber>Senate</chamber><action>Senate Floor Amendment No. 1 Assignments Refers to Health</action>
<statusdate>2/22/2022</statusdate><chamber>Senate</chamber><action>Senate Floor Amendment No. 1 Recommend Do Adopt Health;  013-000-000</action>
<statusdate>2/23/2022</statusdate><chamber>Senate</chamber><action>Second Reading</action>
<statusdate>2/23/2022</statusdate><chamber>Senate</chamber><action>Senate Floor Amendment No. 1 Adopted; Bush</action>
<statusdate>2/23/2022</statusdate><chamber>Senate</chamber><action>Placed on Calendar Order of 3rd Reading February 24, 2022</action>
<statusdate>2/25/2022</statusdate><chamber>Senate</chamber><action>Third Reading - Passed; 049-000-000</action>
<statusdate>2/25/2022</statusdate><chamber>House</chamber><action>Arrived in House</action>
<statusdate>2/25/2022</statusdate><chamber>House</chamber><action>Chief House Sponsor Rep. Kathleen Willis</action>
<statusdate>2/25/2022</statusdate><chamber>House</chamber><action>First Reading</action>
<statusdate>2/25/2022</statusdate><chamber>House</chamber><action>Referred to Rules Committee</action>
<statusdate>3/7/2022</statusdate><chamber>House</chamber><action>Assigned to Prescription Drug Affordability &amp; Accessibility Committee</action>
<statusdate>3/14/2022</statusdate><chamber>House</chamber><action>Added Alternate Co-Sponsor Rep. Nicholas K. Smith</action>
<statusdate>3/15/2022</statusdate><chamber>House</chamber><action>Added Alternate Chief Co-Sponsor Rep. Joyce Mason</action>
<statusdate>3/16/2022</statusdate><chamber>House</chamber><action>Do Pass / Short Debate Prescription Drug Affordability &amp; Accessibility Committee;  016-004-000</action>
<statusdate>3/17/2022</statusdate><chamber>House</chamber><action>Placed on Calendar 2nd Reading - Short Debate</action>
<statusdate>3/22/2022</statusdate><chamber>House</chamber><action>Second Reading - Short Debate</action>
<statusdate>3/22/2022</statusdate><chamber>House</chamber><action>Placed on Calendar Order of 3rd Reading - Short Debate</action>
<statusdate>3/23/2022</statusdate><chamber>House</chamber><action>Added Alternate Co-Sponsor Rep. La Shawn K. Ford</action>
<statusdate>3/23/2022</statusdate><chamber>House</chamber><action>Added Alternate Co-Sponsor Rep. Edgar Gonzalez, Jr.</action>
<statusdate>3/24/2022</statusdate><chamber>House</chamber><action>Added Alternate Co-Sponsor Rep. Kelly M. Cassidy</action>
<statusdate>3/25/2022</statusdate><chamber>House</chamber><action>Added Alternate Chief Co-Sponsor Rep. Deb Conroy</action>
<statusdate>3/29/2022</statusdate><chamber>House</chamber><action>Third Reading - Short Debate - Passed 090-020-000</action>
<statusdate>3/29/2022</statusdate><chamber>Senate</chamber><action>Passed Both Houses</action>
<statusdate>3/29/2022</statusdate><chamber>House</chamber><action>Added Alternate Co-Sponsor Rep. Michael J. Zalewski</action>
<statusdate>3/29/2022</statusdate><chamber>House</chamber><action>Added Alternate Co-Sponsor Rep. Camille Y. Lilly</action>
<statusdate>4/27/2022</statusdate><chamber>Senate</chamber><action>Sent to the Governor</action>
<statusdate>5/6/2022</statusdate><chamber>Senate</chamber><action>Governor Approved</action>
<statusdate>5/6/2022</statusdate><chamber>Senate</chamber><action>Effective Date January 1, 2023</action>
<statusdate>5/6/2022</statusdate><chamber>Senate</chamber><action>Public Act . . . . . . . . . 102-0751</action>
</actions>
</xml>

